Human Anti-MUC1 Recombinant Antibody (clone Clivatuzumab (hPAM4)) (CAT#: HPAB-0207-YJ)

Figure 1 Reaction of several anti-mucin MAbs with PAM4-captured antigen.

Mucin antigens were captured on hPAM4 coated plates, and then probed with several murine anti-mucin MAbs for reaction signal. Both anti-MUC5AC MAbs (2-11 M1 and 45 M1) bound to the hPAM4-captured mucin, whereas the anti-MUC1 MAbs (MA5 and KC4) did not bind. The homologous hPAM4/mPAM4, capture/probe immunoassay gave no signal, suggesting the density of PAM4 epitopes within the mucin may be low, possibly only a single site. A rabbit polyclonal anti-CPM1 IgG was used as a positive control for reaction with hPAM4-captured antigen.

Gold, D. V., Newsome, G., Liu, D., & Goldenberg, D. M. (2013). Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular cancer, 12(1), 143.

Figure 2 Inhibition of hPAM4/antigen binding reaction by murine anti-mucin MAbs.

A) Anti-mucin mMAbs (purified IgG) were added to CPM1-coated plates as potential inhibitors prior to addition of hPAM4. mPAM4 provided almost complete inhibition of the reaction between hPAM4 and antigen with the 45 M1 anti-MUC5AC providing limited inhibitory effect (ICmax = 25.5%). Neither 2-11 M1, anti-MUC5AC nor MA5 and KC4, anti-MUC1 MAbs were able to inhibit the specific hPAM4/antigen reaction. B) A similar inhibition study was performed with several anti-MUC5AC MAbs obtained as ascites fluids. MAbs 21 M1, 62 M1, and 463 M1, anti-MUC5AC provided substantial inhibitory effect, similar to that observed with mPAM4 IgG self-inhibition. The ascites form of 45 M1 yielded an inhibitory effect similar to that of the purified IgG. Ascites containing anti-alpha fetoprotein was employed as a negative control.

Gold, D. V., Newsome, G., Liu, D., & Goldenberg, D. M. (2013). Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Molecular cancer, 12(1), 143.